Ipamorelin: selective GHS-R1a agonist minimal cortisol, prolactin, or appetite effects GHRP-6: GHS-R1a agonist with additional CRH/ACTH activation, prolactin release, and potent orexigenic activity Ipamorelin selectivity ratio (GH:cortisol) is among the highest of all synthetic GHRPs GHRP-6 was instrumental in GHS-R1a receptor identification but is pharmacologically non-selective GH Release Profiles & Pulse Amplitude Both ipamorelin and GHRP-6 stimulate pulsatile GH release from anterior pituitary somatotrophs via GHS-R1a activation, working synergistically with endogenous GHRH
10.1016/j.freeradbiomed.2009.03.004 [DOI] [PMC free article] [PubMed] [Google Scholar] Kato Y., Iwase M., Ichihara S., Kanazawa H., Hashimoto K., Noda A., et al
The blend of Ipamorelin and CJC-1295 without DAC is particularly notable because it aims to produce a sustained elevation in growth hormone levels over time through intermittent administration, making it a subject of interest in studies related to muscle growth, fat loss, and overall metabolic enhancement
Always consult with a healthcare provider before beginning peptide therapy to ensure your treatment is appropriate for your individual health status
Heres why they stand out: Research-Grade Ipamorelin: Xcel Peptides sells only 99%+ pure ipamorelin that is produced in certified American facilities and third-party tested for identity and purity
